Latest news with #Scleroderma
Yahoo
06-05-2025
- Business
- Yahoo
Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025
Quoin Pharmaceuticals, Inc. ASHBURN, Va., May 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to release its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 13, 2025. The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights. About Quoin Pharmaceuticals Ltd. Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, go to: For further information, contact: Quoin Pharmaceuticals Ltd. Michael Myers, Ph.D., CEO mmyers@ Investor Relations PCG Advisory Jeff Ramson jramson@ (646) 863-6341
Yahoo
30-04-2025
- Business
- Yahoo
Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
ASHBURN, Va., April 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the 'Company' or 'Quoin'), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ('Nasdaq') stating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The notification from Nasdaq confirms that for the last 13 consecutive business days, the closing bid price of the Company's ordinary shares was at or above $1.00 per share. Accordingly, Nasdaq considers the matter closed. About Quoin Pharmaceuticals Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. For more information, visit: or LinkedIn for updates. Cautionary Note Regarding Forward Looking StatementsThe Company cautions that statements in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances, such as 'expect,' 'intend,' 'hope,' 'plan,' 'potential,' 'anticipate,' 'look forward,' 'believe,' 'may,' and 'will,' among others. All statements that reflect the Company's expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: Quoin's products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company's ability to deliver a safe and effective treatment for Netherton Syndrome; whether the Company's studies successfully generate data that is sufficiently robust and comprehensive to support an NDA filing for QRX003 as an approved treatment for Netherton Syndrome; and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. For further information, contact:Quoin Pharmaceuticals Myers, Ph.D., CEOmmyers@ Investor RelationsPCG AdvisoryJeff Ramsonjramson@ 863-6341Sign in to access your portfolio
Associated Press
30-04-2025
- Business
- Associated Press
Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
ASHBURN, Va., April 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the 'Company' or 'Quoin'), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ('Nasdaq') stating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The notification from Nasdaq confirms that for the last 13 consecutive business days, the closing bid price of the Company's ordinary shares was at or above $1.00 per share. Accordingly, Nasdaq considers the matter closed. About Quoin Pharmaceuticals Ltd. Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. For more information, visit: or LinkedIn for updates. Cautionary Note Regarding Forward Looking Statements The Company cautions that statements in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances, such as 'expect,' 'intend,' 'hope,' 'plan,' 'potential,' 'anticipate,' 'look forward,' 'believe,' 'may,' and 'will,' among others. All statements that reflect the Company's expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: Quoin's products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company's ability to deliver a safe and effective treatment for Netherton Syndrome; whether the Company's studies successfully generate data that is sufficiently robust and comprehensive to support an NDA filing for QRX003 as an approved treatment for Netherton Syndrome; and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. For further information, contact: Quoin Pharmaceuticals Ltd. Michael Myers, Ph.D., CEO [email protected] Investor Relations PCG Advisory Jeff Ramson [email protected] (646) 863-6341
Yahoo
06-03-2025
- Business
- Yahoo
Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025
ASHBURN, Va., March 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to release its financial results for the fourth quarter and full year ended December 31, 2024, before the market opens on Thursday, March 13, 2025. The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from 2024. About Quoin Pharmaceuticals Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, go to: For further information, contact:Quoin Pharmaceuticals Myers, Ph.D., CEOmmyers@ Investor RelationsPCG AdvisoryJeff Ramson jramson@ (646) 863-6341Sign in to access your portfolio
Yahoo
23-02-2025
- Health
- Yahoo
'My cold fingers were caused by a disease'
About 15 years ago, Tim Holt-Wilson noticed a "gradual degeneration" in the warmth of his fingers. The 66-year-old, who lives near Eye, in Suffolk, had already been diagnosed with the autoimmune condition Scleroderma - which caused stiff skin and inflammation - but he noticed how cold his fingers became. It turned out to be secondary Raynaud's disease - a condition that affected extremities such as the hands or feet during cold temperatures. Mr Holt-Wilson has found ways to cope with his conditions and shared his experience for February's Raynaud's Awareness Month. "I hadn't heard of Scleroderma before then, but I think I had heard of Raynaud's before... but I never thought that was on the path of my life," Mr Holt-Wilson explained. "It's like with all these illnesses you never think when you're younger, 'Oh, that is the trajectory of my existence, that's going to frame my life'. "You just reformulate yourself." According to charity Scleroderma & Raynaud's UK (SRUK), Raynaud's is a common condition that affects up to 10 million people in the UK. When someone with Raynaud's is exposed to the cold, blood vessels in their extremities constrict far more than someone without the disease. This may result in the skin changing colour from white to blue, and then to red, which could be painful, especially when the blood vessels return to normal and circulation was restored. Primary Raynaud's is the milder and most common form of the disease. Secondary Raynaud's, however, is caused by an autoimmune condition and often needs careful monitoring for complications like ulcers or sores. Speaking about triggers, Mr Holt-Wilson explained: "It can happen, for example, in the supermarket when you go near a [freezer], you can feel it in your whole body. "Or when you're holding your [car] steering wheel. "But I've had cold fingers for a lot of my life, but never really figured it was part of this scleroderma syndrome. "I think anybody who suffers from this has got their own techniques for dealing with it." Mr Holt-Wilson explained his Scleroderma meant he lost the effective use of four of his fingers, which have twisted around at right angles to his palm. To manage his Raynaud's, he kept his core temperature and his wrists and hands warm. "Even in summertime, I sometimes wear mittens or particularly wrist warmers," he added. "They are very helpful because they keep the tendons warm on the back of the hand." Mr Holt-Wilson is also able to take a drug called Sildenafil that relaxes the blood vessels and increases blood flow. He described it as a "miracle" for when he undertook geological work outside. For Raynaud's Awareness Month, SRUK is urging the public to take a 60-second online test to find out if they have Raynaud's. "It helps the SRUK get a picture of prevalence of this illness out in the public and it helps research," Mr Holt-Wilson continued. "They're the only UK charity dedicated to helping sufferers so they increase awareness and understanding, and hopefully contribute to research and cures." SRUK originally aimed to reach 10,000 people with the test, but more than 31,000 people have taken it since the campaign launched last November. The charity hoped the test would become the largest citizen science project of its kind into Raynaud's. Follow Suffolk news on BBC Sounds, Facebook, Instagram and X. Man's double hand transplant is 'space-age stuff' 'I used to be scared looking in the mirror' 'I can feel my body turning to stone' Scleroderma & Raynaud's UK
